A Mild Form of RPE65-Associated Retinopathy

Sandrine H. Künzel,Philipp Rating,Marlene Saßmannshausen,Frank G. Holz,Philipp Herrmann
DOI: https://doi.org/10.1055/a-2280-1536
2024-03-22
Klinische Monatsblätter für Augenheilkunde
Abstract:Biallelic mutations in RPE65 give rise to a spectrum of retinal phenotypes ranging from Leber congenital amaurosis (LCA) and early-onset severe retinal dystrophy (EOSRD) to juvenile retinitis pigmentosa (RP) [1], [2]. Since 2017, voretigene neparvovec (VN) has offered the first approved gene therapy in ophthalmology for patients with biallelic mutations in RPE65 , representing a milestone in ophthalmic therapy for inherited retinal dystrophies (IRDs) [3]. We present a rare case of a 42-year-old male with biallelic RPE65 mutations, exhibiting an unusually mild phenotype, questioning the decision for or against subretinal gene therapy under these circumstances. Received: 25 November 2023 Accepted: 19 February 2024 Article published online: 20 March 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
ophthalmology
What problem does this paper attempt to address?